Три ахиллесовы пяты этаноловой септальной аблации

Автор: Каштанов Максим Геннадьевич, Чернышев С.Д., Кардапольцев Л.В., Бердников С.В., Идов Э.М.

Журнал: Патология кровообращения и кардиохирургия @journal-meshalkin

Статья в выпуске: 3 т.21, 2017 года.

Бесплатный доступ

В статье рассмотрены основные недостатки этаноловой септальной аблации у пациентов с обструктивной гипертрофической кардиомиопатией. К ним относятся высокостепенные атриовентрикулярные блокады, резидуальная обструкция выходного тракта левого желудочка и так называемые проаритмические эффекты этаноловой септальной аблации. Представленные «слабости» процедуры рассмотрены в аспекте их распространенности, этиологии и профилактики.

Гипертрофическая кардиомиопатия, обструкция выходного тракта левого желудочка, этаноловая септальная аблация, атриовентрикулярные блокады, резидуальная обструкция выходного тракта левого желудочка, проаритмические эффекты этаноловой септальной аблации

Еще

Короткий адрес: https://sciup.org/142140802

IDR: 142140802 | DOI: 10.21688-1681

Список литературы Три ахиллесовы пяты этаноловой септальной аблации

Бокерия Л.А., Гудкова Р.Г. Сердечно-сосудистая хирургия -2014. М: Научный центр сердечно-сосудистой хирургии им. А.Н. Бакулева РАМН, 2015. 226 с.
Maron B.J., Gardin J.M., Flack J.M., Gidding S.S., Kurosaki T.T., Bild D.E. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation. 1995;92(4):785-9. http://dx.doi.o PMID: 7641357 DOI: rg/10.1161/01.CIR.92.4.785
Gersh B.J., Maron B.J., Bonow R.O., Dearani J.A., Fifer M.A., Link M.S., Naidu S.S., Nishimura R.A., Ommen S.R., Rakowski H., Seidman C.E., Towbin J.A., Udelson J.E. and Yancy C.W. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;124(24):2761-96. http://dx.doi.o PMID: 22068435 DOI: rg/10.1161/CIR.0b013e318223e230
Maron B.J., Yacoub M., Dearani J.A. Controversies in cardiovascular medicine. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients. Eur HeartJ. 2011;32(9):1055-8. http://dx.doi.org/10.1093/eurheartj/ehr006 PMID: 21324934
Veselka J., Jensen M.K., Liebregts M., Januska J., Krejci J., Bartel T., Dabrowski M., Hansen P.R., Almaas V.M., Seggewiss H., Horstkotte D., Tomasov P., Adlova R., Bundgaard H., Steggerda R., Ten Berg J., Faber L. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J. 2016;37(19):1517-23 http://dx.doi. org/10.1093/eurheartj/ehv693. PMID: 26746632
Nagueh S.F., Groves B.M., Schwartz L., Smith K.M., Wang A., Bach R.G., Nielsen C., Leya F., Buergler J.M., Rowe S.K. et al. 2011 Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy a multicenter North American registry. J Am Coll Cardiol. 2011;58(2):2322-8. http://dx.doi. org/10.1016/j.jacc.2011.06.073
Agarwal S., Tuzcu E.M., Desai M.Y., Smedira N., Lever H.M., Lytle B.W., Kapadia S.R. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;55(8):823-34. http://dx.doi.org/10.1016/j. jacc.2009.09.047PMID: 20170823.
Liebregts M., Vriesendorp P.A., Mahmoodi B.K., Schinkel A.F., Michels M., ten Berg J.M. A Systematic Review and Meta-Analysis of Long-Term Outcomes After Septal Reduction Therapy in Patients With Hypertrophic Cardiomyopathy. JACC Heart Fail. 2015;3(11):896-905. http://dx.doi.o PMID: 26454847 DOI: rg/10.1016Zj.jchf.2015.06.011
Singh K., Qutub M., Carson K., Hibbert B., Glover C. A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc Interv. 2016;88(1):107-15. http://dx.doi.org/10.1002/ccd.26293 PMID: 26526299
El-Jack S.S., Nasif M., Blake J.W., Dixon S.R., Grines C.L., O’Neill W.W. Predictors of complete heart block after alcohol septal ablation for hypertrophic cardiomyopathy and the timing of pacemaker implantation. J Interv Cardiol. 2007;20(1):73-6. PMID: 17300408
Lawrenz T., Lieder F., Bartelsmeier M., Leuner C., Borchert B., Meyer zu Vilsendorf D., Strunk-Mueller C., Reinhardt J., Feuchtl A., Stellbrink C., Kuhn H. Predictors of complete heart block after transcoronary ablation of septal hypertrophy: results of a prospective electrophysiological investigation in 172 patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2007;49(24):2356-63 PMID: 17572252
Axelsson A., Weibring K., Havndrup O., Kelbaek H., Jorgensen E., Helqvist S., Iversen K., Kober L., Bundgaard H., Jensen M.K. Atrioventricular conduction after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. J Cardiovasc Med (Hagerstown). 2014;15(3):214-21. http://dx.doi.org/10.2459/JCM.0b013e3283638073 PMID: 24662414
Talreja D.R., Nishimura R.A., Edwards W.D., Valeti U.S., Ommen S.R., Tajik A.J., Dearani J.A., Schaff H.V., Holmes D.R. Jr. Alcohol septal ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue. J Am Coll Cardiol. 2004;44(12):2329-32 PMID: 15607394
Veselka J., Zemanek D., Tomasov P., Homolova S., Adlova R., Tesar D. Complications of low-dose, echo-guided alcohol septal ablation. Catheter Cardiovasc Interv. 2010;75(4):546-50. http://dx.doi.o 20014165 DOI: rg/10.1002/ccd.22326PMID:
Faber L., Welge D., Fassbender D., Schmidt H.K., Horstkotte D., Seggewiss H. Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: managing the risk of procedure-related AV conduction disturbances. Int J Cardiol. 2007;119(2):163-7. http://dx.doi.o PMID: 17067708 DOI: rg/10.1016/jjjcard.2006.07.179
Cho Y.H., Quintana E., Schaff H.V., Nishimura R.A., Dearani J.A., Abel M.D., Ommen S. Residual and recurrent gradients after septal myectomy for hypertrophic cardiomyopathy-mechanisms of obstruction and outcomes of reoperation. J Thorac Cardiovasc Surg. 2014;148(3):909-15; discussion 915-6. http://dx.doi.org/10.1016/j. jtcvs.2014.05.028 PMID: 24930617
Lu M., Du H., Gao Z., Song L., Cheng H., Zhang Y., Yin G., Chen X., Ling J., Jiang Y., Wang H., Li J., Huang J., He Z., Zhao S. Predictors of Outcome After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: An Echocardiography and Cardiovascular Magnetic Resonance Imaging Study. Circ Cardiovasc Interv. 2016;9(3):e002675. http://dx.doi.org/10.1161/CIRCINTERVENTIONS.115.002675 PMID: 26884612
Sorajja P., Ommen S.R., Holmes D.R. Jr, Dearani J.A., Rihal C.S., Gersh B.J., Lennon R.J., Nishimura R.A. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2012;126(20):2374-80. http://dx.doi.org/10.1161/ href='contents.asp?titleid=14507' title='Circulation'>CirculationAHA.111.076257. PMID: 23076968
Jensen M.K., Almaas V.M., Jacobsson L., Hansen P.R., Havndrup O., Aakhus S., Svane B., Hansen T.F., Kober L., Endresen K., Eriksson M.J., Jorgensen E., Amlie J.P., Gadler F., Bundgaard H. Long-term outcome of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: a Scandinavian multicenter study. Circ Cardiovasc Interv. 2011;4(3):256-65. http://dx.doi.org/10.1161/CIRCINTERvENTIONS.110.959718PMID: 21540441
Schäfer U., Kreidel F., Frerker C. MitraClip implantation as a new treatment strategy against systolic anterior motion-induced outflow tract obstruction in hypertrophic obstructive cardiomyopathy. Heart Lung Circ. 2014;23(5):e131-5. http://dx.doi. org/10.1016/j.hlc.2014.01.007 PMID: 24698439
Veselka J., Krejci.J, Tomasov P., Zemanek D. Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population. Eur Heart J. 2014;35(30):2040-5. http://dx.doi.o PMID: 24464834 DOI: rg/10.1093/eurheartj/eht495
Chang S.M., Lakkis N.M., Franklin J., Spencer W.H. 3rd, Nagueh S.F. Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation. 2004;109(7):824-7. http://dx.doi.o. CIR.0000117089.99918.5A PMID: 14967729 DOI: rg/10.1161/01
Chang S.M., Nagueh S.F., Spencer W.H. 3rd, Lakkis N.M. Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol. 2003;42(2):296-300. PMID: 12875767
Yoerger D.M., Picard M.H., Palacios I.F., Vlahakes G.J., Lowry P.A., Fifer M.A. Time course of pressure gradient response after first alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2006;97(10):1511-4. http://dx.doi. org/10.1016/j.amjcard.2005.12.040 PMID: 16679095
van der Lee C., ten Cate F.J., Geleijnse M.L., Kofflard M.J., Pedone C., van Herwerden L.A., Biagini E., Vletter W.B., Serruys P.W. Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets. Circulation. 2005;112(4):482-8. https://doi. org/10.1161/CirculationAHA.104.508309
Fernandes V.L., Nielsen C., Nagueh S.F., Herrin A.E., Slifka C., Franklin J., Spencer W.H. 3rd. Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy the Baylor and Medical University of South Carolina experience 1996 to 2007. JACC Cardiovasc Interv. 2008;1(5):561-70. http://dx.doi. org/10.1016/j.jcin.2008.07.005 PMID: 19463359
Patel P., Dhillon A., Popovic Z.B., Smedira N.G., Rizzo J., Thamilarasan M., Agler D., Lytle B.W., Lever H.M., Desai M.Y. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients without severe septal hypertrophy: implications of mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography. Circ Cardiovasc Imaging. 2015;8(7):e003132. http://dx.doi. org/10.1161/CIRCIMAGING.115.003132 PMID: 26082555
Kim D.-H., Handschumacher M.D., Levine R.A., Choi Y.-S., Kim Y.J., Yun S.-C., Song J.-M., Kang D.-H., Song J.-K. In vivo measurement of mitral leaflet surface area and subvalvular geometry in patients with asymmetrical septal hypertrophy: insights into the mechanism of outflow tract obstruction. Circulation. 2010;122(13):1298-307. http://doi.org/10.1161/ href='contents.asp?titleid=14507' title='Circulation'>CirculationAHA.109.935551
Kitamura M., Amano Y., Takayama M., Shibuya J., Matsuda J., Sangen H., Nakamura S., Takano H., Asai K., Shimizu W. Abstract 16703: extended non-anteroseptal region left ventricular hypertrophy predicts repeat alcohol septal ablation for refractory hypertrophic obstructive cardiomyopathy: morphological investigation using cardiac magnetic resonance. Circulation. 2015;132(Suppl 3):A16703.
Faber L., Welge D., Fassbender D., Schmidt H.K., Horstkotte D., Seggewiss H. One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response. Clin Res Cardiol. 2007;96(12):864-73. http://doi.org/10.1007/s00392-007-0578-9 PMID: 17891518
Veselka J., Tomasov P., Januska J., Krejci J., Adlova R. Obstruction after alcohol septal ablation is associated with cardiovascular mortality events. Heart. 2016;102:1793-6. http://doi.org/10.1136/ href='contents.asp?titleid=16739' title='Heart (British Cardiac Society)'>Heartjnl-2016-309699. PMID: 27587438
Kwon D.H., Smedira N.G., Popovic Z.B., Lytle B.W., Setser R.M., Thamilarasan M., Schoenhagen P., Flamm S.D., Lever H.M., Desai M.Y. Steep left ventricle to aortic root angle and hypertrophic obstructive cardiomyopathy: study of a novel association using three-dimensional multimodality imaging. Heart. 2009;95(21):1784-91. http://doi.org/10.1136/hrt.2009.166777. PMID: 19549621
Valeti U.S., Nishimura R.A., Holmes D.R., Araoz P.A., Glockner J.F., Breen J.F., Ommen S.R., Gersh B.J., Tajik A.J., Rihal C.S., Schaff H.V., Maron B.J. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2007;49(3):350-7. PMID: 17239717
Maron M.S., Olivotto I., Betocchi S., Casey S.A., Lesser J.R., Losi M.A., Cecchi F., Maron B.J. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348(4):295-303. http://doi.org/10.1056/NEJMoa021332
Noseworthy P.A., Rosenberg M.A., Fifer M.A., Palacios I.F., Lowry P.A., Ruskin J.N., Sanborn D.M., Picard M.H., Vlahakes G.J., Mela T., Das S. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2009;104(1):128-32. http://doi.org/10.1016 Zj.amjcard.2009.02.056
Leonardi R.A., Kransdorf E.P., Simel D.L., Wang A. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv. 2010;3(2):97-104. http://doi.org/10.1161CIRCINTERVENTIONS.109.916676 PMID: 20197511
Kuhn H., Lawrenz T., Lieder F., Leuner C., Strunk-Mueller C., Obergassel L., Bartelsmeier M., Stellbrink C. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience. Clin Res Patologiya krovoobrashcheniya i kardiokhirurgiya. 2017;21 (3):12-22
ten Cate F.J., Soliman O.I., Michels M., Theuns D.A., de Jong P.L., Geleijnse M.L., Serruys P.W. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. Circ Heart Fail. 2010;3(3):362-9. http://doi. org/10.1161/CIRCHEARTFAILURE.109.862359
Maron B.J., Spirito P., Shen W.K., Haas T.S., Formisano F., Link M.S., Epstein A.E., Almquist A.K., Daubert J.P., Lawrenz T., Boriani G., Estes N.A. 3rd, Favale S., Piccininno M., Winters S.L., Santini M., Betocchi S., Arribas F., Sherrid M.V., Buja G., Semsarian C., Bruzzi P. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298(4):405-12. Erratum in: JAMA. 2007;298(13):1516. http://doi.org/10.1001/ href='contents.asp?titleid=6595' title='JAMA'>JAMA.298.4.405 PMID: 17652294
Balt J.C., Wijffels M.C., Boersma L.V., Wever E.F., ten Berg J.M. Continuous rhythm monitoring for ventricular arrhythmias after alcohol septal ablation for hypertrophic cardiomyopathy. Heart. 2014;100(23):1865-70. http://doi.org/10.1136/ href='contents.asp?titleid=16739' title='Heart (British Cardiac Society)'>Heartjnl-2014-305593 PMID: 25073885
Hori Y., Ueda M., Nakayama T., Saegusa N., Uehara M., Lee K., Sekine T., Daimon M., Kobayashi Y., Funabashi N., Komuro I. Occurrence of de novo sustained monomorphic ventricular tachycardia induced after percutaneous transluminal alcohol septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Int J Cardiol. 2007;119(3):403-7. http://doi.org/10.1016/j. ijcard.2006.07.182
McGregor J.B., Rahman A., Rosanio S., Ware D., Birnbaum Y., Saeed M. Monomorphic ventricular tachycardia: a late complication of percutaneous alcohol septal ablation for hypertrophic cardiomyopathy. Am J Med Sci. 2004;328(3):185-8. PMID: 15367880.
Boltwood C.M. Jr, Chien W., Ports T. Ventricular tachycardia complicating alcohol septal ablation. N Engl J Med. 2004;351(18):1914-5. http://doi.org/10.1056/NEJM200410283511824
Simon R.D., Crawford F.A. 3rd, Spencer W.H. 3rd, Gold M.R. Sustained ventricular tachycardia following alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol. 2005;28(12):1354-6. http://doi.org/10.1111Zj.1540-8159.2005.00278.x PMID: 16403169
Cuoco F.A., Spencer W.H. 3rd, Fernandes V.L., Nielsen C.D., Nagueh S., Sturdivant J.L., Leman R.B., Wharton J.M., Gold M.R. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;52(21):1718 23. http://doi.org/10.1016/jjacc.2008.07.061 PMID: 19007692
Vriesendorp P.A., Liebregts M., Steggerda R.C., Schinkel A.F., Willems R., Ten Cate F.J., van Cleemput J., Ten Berg J.M., Michels M. Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy. JACC Heart Fail. 2014;2(6):630-6. http://doi.org/10.1016/j.jchf.2014.06.012 PMID: 25447346
Jensen M.K., Prinz C., Horstkotte D., van Buuren F., Bitter T., Faber L., Bundgaard H. Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Heart. 2013;99(14):1012-7. http://doi.org/10.1136/ href='contents.asp?titleid=16739' title='Heart (British Cardiac Society)'>Heartjnl-2012-303339 PMID: 23644300
Elliott P.M., Anastasakis A., Borger M.A., Borggrefe M., Cecchi F., Charron P., Hagege A.A., Lafont A., Limongelli G., Mahrholdt H., McKenna W.J., Mogensen J., Nihoyannopoulos P., Nistri S., Pieper P.G., Pieske B., Rapezzi C., Rutten F.H., Tillmanns C., Watkins H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. http://doi.org/10.1093/eurheartj/ehu284 PMID: 25173338
Futami C., Tanuma K., Tanuma Y., Saito T. The arterial blood supply of the conducting system in normal human hearts. Surg Radiol Anat 2003;25(1):42-9. http://doi.org/10.1007/s00276-002-0085-7 PMID: 12819949
Sherrid M.V., Arabadjian M. Echocardiography to individualize treatment for hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 2012;54(6):461-76. http://doi.org/10.1016/j.pcad.2012.04.007 PMID: 22687587
Musat D., Sherrid M.V. Pathophysiology of hypertrophic cardiomyopathy determines its medical treatment. Anadolu Kardiyol Derg. 2006;6(Suppl 2):9-17. PMID: 17162264
Cavalcante J.L., Barboza J.S., Lever H.M. Diversity of mitral valve abnormalities in obstructive hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 2012;54(6):517-22. http://doi.org/10.1016/j. pcad.2012.03.002 PMID: 22687594
Veselka J., Kreja J., Tomasov P., Durdil V., Riedlbauchova L., Honek J., Honek T., Zemanek D. Outcome of patients after alcohol septal ablation with permanent pacemaker implanted for periprocedural complete heart block. Int J Cardiol. 2014;171(2):e37-8. http://doi. org/10.1016/j.ijcard.2013.11.119 PMID: 24360153
Martin R., Lairez O., Boudou N., Mejean S., Lhermusier T., Dumonteil N., Berry M., Cognet T., Massabuau P., Elbaz M., Rousseau H., Galinier M., Carrie D. Relation between left ventricular outflow tract obstruction and left ventricular shape in patients with hypertrophic cardiomyopathy: a cardiac magnetic resonance imaging study. Arch Cardiovasc Dis. 2013;106(8-9):440-7. http://doi.org/10.1016/j.acvd.2013.05.002 PMID: 23906680
Harrigan C.J., Appelbaum E., Maron B.J., Buros J.L., Gibson C.M., Lesser J.R., Udelson J.E., Manning W.J., Maron M.S. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol. 2008;101(5):668-73. http://doi.org/10.1016/j.amjcard.2007.10.032
Kwon D.H., Setser R.M., Thamilarasan M., Popovic Z.V., Smedira N.G., Schoenhagen P., Garcia M.J., Lever H.M., Desai M.Y. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Heart. 2008;94(10):1295-301. http://doi.org/10.1136/hrt.2007.118018 PMID: 17690158
Adabag A.S., Maron B.J., Appelbaum E., Harrigan C.J., Buros J.L., Gibson C.M., Lesser J.R., Hanna C.A., Udelson J.E., Manning W.J., Maron M.S. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51(14):1369-74. http://doi.org/10.1016/j.jacc.2007.11.071 PMID: 18387438
Choudhury L., Mahrholdt H., Wagner A., Choi K.M., Elliott M.D., Klocke F.J., Bonow R.O., Judd R.M., Kim R.J. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;40(12):2156-64. PMID: 12505229
Kwon D.H., Setser R.M., Popovic Z.B., Thamilarasan M., Sola S., Schoenhagen P., Garcia M.J., Flamm S.D., Lever H.M., Desai M.Y. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study. Int J Cardiovasc Imaging. 2008;24(6):617-25. http://doi.org/10.1007/s10554-008-9292-6 PMID: 18204915
Moon J.C., McKenna W.J., McCrohon J.A., Elliott P.M., Smith G.C., Pennell D.J. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003;41(9):1561-7. PMID: 12742298
Austin B.A., Kwon D.H., Smedira N.G., Thamilarasan M., Lever H.M., Desai M.Y. Abnormally thickened papillary muscle resulting in dynamic left ventricular outflow tract obstruction: an unusual presentation of hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2009;22(1):105.e5-6. http://doi.org/10.1016/j. echo.2008.10.022 PMID: 19131012
Sung K.-T., Yun C.-H., Hou C. J.-Y., Hung C.-L. Solitary accessory and papillary muscle hypertrophy manifested as dynamic mid-wall obstruction and symptomatic heart failure: diagnostic feasibility by multi-modality imaging. BMC Cardiovascular Disorders. 2014;14:34. http://doi.org/10.1186/1471-2261-14-34
Shah A.S., Kukar A., Chaudhry F.A., Sherrid M.V. Unusual anomalous single papillary muscle causing symptomatic mid-left ventricular cavity obstruction: octopus papillary muscle. J Am Soc Echocardiogr. 2006;19(7):939.e9-11. http://doi.org/10.1016/j. echo.2006.03.014 PMID: 16825011
Klues H.G., Roberts W.C., Maron B.J. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction. Circulation. 1991;84(3):1188-97. PMID: 1884449
Minakata K., Dearani J.A., Schaff H.V., O’Leary P.W., Ommen S.R., Danielson G.K. Mechanisms for recurrent left ventricular outflow tract obstruction after septal myectomy for obstructive hypertrophic cardiomyopathy. Ann Thorac Surg. 2005;80(3):851-6. PMID: 16122442
Ferrazzi P., Spirito P., Iacovoni A., Calabrese A., Migliorati K., Simon C., Pentiricci S., Poggio D., Grillo M., Amigoni P., Iascone M., Mortara A., Maron B.J., Senni M., Bruzzi P. Transaortic Chordal Cutting: Mitral Valve Repair for Obstructive Hypertrophic Cardiomyopathy With Mild Septal Hypertrophy. J Am Coll Cardiol. 2015;66(15):1687-96. http://doi.org/10.1016/j.jacc.2015.07.069 PMID: 26449139
Maron B.J., Harding A.M., Spirito P., Roberts W.C., Waller B.F. Systolic anterior motion of the posterior mitral leaflet: a previously unrecognized cause of dynamic subaortic obstruction in patients with hypertrophic cardiomyopathy. Circulation. 1983;68(2):282-93. PMID: 6683131.
Cape E.G., Simons D., Jimoh A., Weyman A.E., Yoganathan A.P., Levine R.A. Chordal geometry determines the shape and extent of systolic anterior motion: in-vitro studies. J Am Coll Cardiol. 1989;13:1438-48. PMID: 2703621
Bogachev-Prokophiev A., Zheleznev S., Fomenko M., Pivkin A., Afanasiev A., Sharifulin R., Karaskov A. Mitral subvalvular apparatus intervention in patients with obstructive hypertrophic cardiomyopathy: does it need? J Cardiothorac Surg. 2015;10(Suppl 1):A138. http://doi.org/10.1186/1749-8090-10-S1-A138

Еще

Статья научная